Rznomics

Rznomics Inc., a South Korean biopharmaceutical company specializing in RNA-based gene therapies, announced it is joining Lilly Gateway Labs in San Diego, California. The move is intended to accelerate candidate discovery and development across its target gene database bank of over 200 disease targets, while also supporting long-term efforts to establish global clinical infrastructure for its lead pipelines, expand global strategic partnerships, and recruit top-tier R&D researchers in the U.S. Lilly Gateway Labs is an innovation hub that provides wet lab facilities and opportunities to engage with Lilly scientists and executives, and is part of Lilly Catalyze360 alongside Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab. Rznomics CEO Seong-Wook Lee called the entry a meaningful milestone for the company's proprietary RNA platform, and said the company intends to advance development and commercialization of its RNA therapeutics through active collaboration with the global biotech ecosystem. Rznomics signed a research collaboration and license agreement with Eli Lilly and Company in May 2025 for development of a novel RNA editing therapeutic, and listed on the KOSDAQ market in December 2025.